HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis

Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short of expectations, crashing the biotech’s stock as investors evaluated the fallout from a key readout expected to validate its platform.

By FierceBiotech · May 9, 2026 · via FierceBiotech
Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Cytokinetics’ Myqorzo Delivers Landmark Phase 3 Win in Non‑Obstructive HCM
PipelineBriefing
Cytokinetics’ Myqorzo Delivers Landmark Phase 3 Win in Non‑Obstructive HCM
By succeeding in the ACACIA-HCM trial, Myqorzo could become the first approved treatment for non‑obstructive h…
May 6, 2026
FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
PipelineFiercePharma ↗
FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
The early FDA approval doesn't change Pfizer and Arvinas' plan to leave commercialization of the drug to a yet…
May 4, 2026
J&J axes $5B CAR-T dream months after touting best-in-disease efficacy
PipelineFierceBiotech ↗
J&J axes $5B CAR-T dream months after touting best-in-disease efficacy
Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliv…
May 4, 2026